Setting traps for NKG2A gives NK cell immunotherapy a fighting chance
JOURNAL OF CLINICAL INVESTIGATION
Authors: Cichocki, Frank; Miller, Jeffrey S.
Abstract
The equilibrium of signaling through activating and inhibitory receptors dictates whether a given NK cell will execute cellular cytotoxicity. In this issue of the JCI, Kamiya et al. describe a novel approach to efficiently inhibiting surface expression of the inhibitory receptor CD94/NK group 2 member A (NKG2A) through retention of the protein in the endoplasmic reticulum. In adoptive transfer experiments into tumor-bearing immunodeficient mice, NKG2A(null) NK cells were significantly more effective at eliminating HLA-E-expressing tumor cells than NKG2A(+) NK cells. This study provides proof of concept for a new immunotherapeutic approach using NKG2A(null) NK cells.
Variation in genetic polymorphisms and gene expression of HLA-E to predict outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI/cetuximab: Data from the phase III FIRE-3 trial
JOURNAL OF CLINICAL ONCOLOGY
Authors: Naseem, Madiha; Cao, Shu; Stintzing, Sebastian; Battaglin, Francesca; Tokunaga, Ryuma; Puccini, Alberto; Berger, Martin D.; Soni, Shivani; Zhang, Wu; Barzi, Afsaneh; Heinemann, Volker; Lenz, Heinz-Josef
Abstract
COA
Publication 
Loading ......
